Vasopressin
Highest phase reached
Approved
Drug type
Protein
First approval year
2014
- First approval year
- 2014
- Listing at source
- Listed
- Highest phase reached
- Approved
- Drug type
- Protein
- Drug name
- Vasopressin
- Molecular weight
- 1,084.25
- Structure (SMILES)
- N=C(N)NCCC[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N1)C(=O)NCC(N)=O
- beta hypophamine
- Beta-hypophamine
- leiormone
- Leiormone
- vasophysin
- Vasophysin
- vasopressin component of hbn 1
- Vasopressin component of hbn-1
- vasostrict
- Vasostrict
- 8 l argininevasopressin
- 8-L-ARGININEVASOPRESSIN
- arginin vasopressin
- arginine vasopressin
- Arginine vasopressin
- Arginine Vasopressin
- ARGININE VASOPRESSIN [MI]
- arginine vasopressin mi
- argipressin
- Argipressin
- argipressin [INN]
- ARGIPRESSIN [MART.]
- Argipressin [WHO-DD]
- argipressin inn
- argipressin mart
- argipressin or lypressin
- Argipressin or lypressin
- argipressin who dd
- cys tyr phe gln asn cys pro arg gly nh2 1 6 disulphide
- CYS-TYR-PHE-GLN-ASN-CYS-PRO-ARG-GLY-NH2 (1-6 DISULPHIDE)
- hbn 1 component vasopressin
- HBN-1 COMPONENT VASOPRESSIN
- inyectable de vasopresina
- Inyectable de vasopresina
- solute injectable de vasopressine
And 21 more, listed on the interactive page.
- CAS registry numbers
- 113-79-1
- ChEMBL ID
- CHEMBL373742
- InChIKey
- KBZOIRJILGZLEJ-LGYYRGKSSA-N
- PubChem compound IDs
- 644077
- RxNorm IDs (RxCUI)
- 11149
- FDA ingredient codes (UNII)
- Y4907O6MFD
- Applicant
- AM REGENT
- Approval date
- 3 Aug 2020
- Application number
- NDA212593
- Patents
- 16
- Designations
- 0
- Earliest recorded loss of exclusivity
- 27 Sept 2044
- First in class
- No
- Fast track
- No
- Breakthrough designation
- No
- Orphan designation
- No
- Priority review
- No
- Orphan exclusivity
- No
- Accelerated approval
- No
- Availability
- Prescription only
- Pharmacology name
- vasopressin
- Type
- Peptide
- Drug name stem
- -pressin
- Approval recorded by Guide to Pharmacology
- Yes
Administration routes
- Parenteral
- Mechanism
- Vasopressin receptor agonist
- Action type
- Agonist
- Target
- Vasopressin receptor
- Protein identifier
- P30518
- Mechanism
- Vasopressin receptor agonist
- Action type
- Agonist
- Target
- Vasopressin receptor
- Protein identifier
- P37288
- Mechanism
- Vasopressin receptor agonist
- Action type
- Agonist
- Target
- Vasopressin receptor
- Protein identifier
- P47901
- Action
- Full agonist
- Action type
- FULL_AGONIST
- Target
- V2 receptor
- Gene symbol
- AVPR2
- Protein identifier
- P30518
- Affinity units
- pKi
- Primary target
- Yes
- Action
- Full agonist
- Action type
- FULL_AGONIST
- Target
- V1A receptor
- Gene symbol
- AVPR1A
- Protein identifier
- P37288
- Affinity units
- pKi
- Primary target
- Yes
- Action
- Full agonist
- Action type
- FULL_AGONIST
- Target
- V1B receptor
- Gene symbol
- AVPR1B
- Protein identifier
- P47901
- Affinity units
- pKi
- Primary target
- Yes
- Action
- Partial agonist
- Action type
- PARTIAL_AGONIST
- Target
- OT receptor
- Gene symbol
- OXTR
- Protein identifier
- P30559
- Affinity units
- pKi
Open Targets mechanisms
- Mechanism
- Vasopressin receptor agonist
- Action type
- Agonist
- Target
- Vasopressin receptor
- Action type
- Agonist
- Gene symbol
- AVPR2
- Protein identifier
- P30518
- Organism
- Homo sapiens
- Target development level
- Clinical
- Action type
- Agonist
- Gene symbol
- AVPR1A
- Protein identifier
- P37288
- Organism
- Homo sapiens
- Target development level
- Clinical
- Action type
- Agonist
- Gene symbol
- AVPR1B
- Protein identifier
- P47901
- Organism
- Homo sapiens
- Target development level
- Clinical
- Condition
- Child Development Disorders, Pervasive
- Highest recorded phase
- 2
- Condition identifier
- EFO:0003756
- Subject identifier
- D002659
- Condition
- Autistic Disorder
- Highest recorded phase
- 2
- Condition identifier
- EFO:0003758
- Subject identifier
- D001321
- Condition
- Heart Diseases
- Highest recorded phase
- 3
- Condition identifier
- EFO:0003777
- Subject identifier
- D006331
- Condition
- Pain
- Highest recorded phase
- 3
- Condition identifier
- EFO:0003843
- Subject identifier
- D010146
- Condition
- Death, Sudden, Cardiac
- Highest recorded phase
- 2
- Condition identifier
- EFO:0004278
- Subject identifier
- D016757
- Condition
- Acute Lung Injury
- Highest recorded phase
- 2
- Condition identifier
- EFO:0004610
- Subject identifier
- D055371
- Condition
- Hernias, Diaphragmatic, Congenital
- Highest recorded phase
- 2
- Condition identifier
- EFO:0005207
- Subject identifier
- D065630
- Condition
- Hypotension
- Highest recorded phase
- 0.5
- Condition identifier
- EFO:0005251
- Subject identifier
- D007022
- Condition
- Shock, Septic
- Highest recorded phase
- 3
- Condition identifier
- EFO:0006834
- Subject identifier
- D012772
- Condition
- Heart Arrest
- Highest recorded phase
- 3
- Condition identifier
- EFO:0009492
- Subject identifier
- D006323
- Condition
- Pleural Effusion
- Highest recorded phase
- 2
- Condition identifier
- EFO:0009637
- Subject identifier
- D010996
- Condition
- Abortion, Spontaneous
- Highest recorded phase
- 1
- Condition identifier
- EFO:1001255
- Subject identifier
- D000022
- Condition
- Shock
- Highest recorded phase
- 3
- Condition identifier
- HP:0031273
- Subject identifier
- D012769
- Condition
- Sepsis
- Highest recorded phase
- 4
- Condition identifier
- HP:0100806
- Subject identifier
- D018805
- Condition
- Leiomyoma
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0001572
- Subject identifier
- D007889
- Condition
- Depressive Disorder, Major
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0002009
- Subject identifier
- D003865
- Condition
- Syndrome
- Highest recorded phase
- 3
- Condition identifier
- MONDO:0002254
- Subject identifier
- D013577
- Condition
- Myoma
- Highest recorded phase
- 3
- Condition identifier
- MONDO:0003061
- Subject identifier
- D009214
- Condition
- Diabetes Insipidus
- Highest recorded phase
- 4
- Condition identifier
- MONDO:0004782
- Subject identifier
- D003919
- Condition
- Hypertension, Pulmonary
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0005149
- Subject identifier
- D006976
- Condition identifier
- EFO_0000714
- Highest recorded phase
- 3
- Condition identifier
- EFO_0003756
- Condition identifier
- EFO_0003758
- Condition identifier
- EFO_0003777
- Highest recorded phase
- 3
- Condition identifier
- EFO_0004278
- Highest recorded phase
- 2
- Condition identifier
- EFO_0004610
- Highest recorded phase
- 2
- Condition identifier
- EFO_0005251
- Condition identifier
- EFO_0006834
- Highest recorded phase
- 3
- Condition identifier
- EFO_0009492
- Highest recorded phase
- 3
- Condition identifier
- EFO_0009516
- Condition identifier
- EFO_0009909
- Highest recorded phase
- 2
- Condition identifier
- EFO_1001255
- Highest recorded phase
- 3
- Condition identifier
- EFO_1001373
- Highest recorded phase
- 3
- Condition identifier
- HP_0000083
- Condition identifier
- HP_0000103
- Condition identifier
- HP_0000103
- Highest recorded phase
- 4
- Condition identifier
- HP_0000131
- Condition identifier
- HP_0000822
- Highest recorded phase
- 2
- Condition identifier
- HP_0001662
- Highest recorded phase
- 1
- Condition identifier
- HP_0002637
- Condition identifier
- HP_0012531
- Highest recorded phase
- 1
- Condition identifier
- HP_0012531
- Highest recorded phase
- 3
- Condition identifier
- HP_0031273
- Highest recorded phase
- 3
- Condition identifier
- HP_0100806
- Condition identifier
- HP_0100806
- Highest recorded phase
- 4
And 20 more, listed on the interactive page.
- Event
- acidosis
- Reports
- 4
- Reporting signal score
- 8.28738
- Event
- acute kidney injury
- Reports
- 25
- Reporting signal score
- 26.3757
- Event
- anuria
- Reports
- 9
- Reporting signal score
- 24.2239
- Event
- arteriospasm coronary
- Reports
- 8
- Reporting signal score
- 24.7265
- Event
- bradycardia
- Reports
- 12
- Reporting signal score
- 11.4899
- Event
- carcinoid crisis
- Reports
- 3
- Reporting signal score
- 15.4847
- Event
- cardiac arrest
- Reports
- 25
- Reporting signal score
- 60.793
- Event
- cardiac failure
- Reports
- 9
- Reporting signal score
- 8.68559
- Event
- cardiogenic shock
- Reports
- 36
- Reporting signal score
- 138.927
- Event
- cardiotoxicity
- Reports
- 8
- Reporting signal score
- 20.3341
- Event
- circulatory collapse
- Reports
- 8
- Reporting signal score
- 16.3925
- Event
- coma scale abnormal
- Reports
- 5
- Reporting signal score
- 13.8637
- Event
- compartment syndrome
- Reports
- 6
- Reporting signal score
- 19.5261
- Event
- condition aggravated
- Reports
- 18
- Reporting signal score
- 8.13806
- Event
- crush syndrome
- Reports
- 2
- Reporting signal score
- 10.5384
- Event
- cyanosis
- Reports
- 10
- Reporting signal score
- 22.3314
- Event
- diabetes insipidus
- Reports
- 21
- Reporting signal score
- 98.4405
- Event
- disseminated intravascular coagulation
- Reports
- 6
- Reporting signal score
- 12.4837
- Event
- distributive shock
- Reports
- 8
- Reporting signal score
- 35.5648
- Event
- drug-device interaction
- Reports
- 2
- Reporting signal score
- 11.329
- Event
- dry gangrene
- Reports
- 8
- Reporting signal score
- 41.8072
- Event
- electrocardiogram qrs complex prolonged
- Reports
- 5
- Reporting signal score
- 12.486
- Event
- electrocardiogram st segment elevation
- Reports
- 4
- Reporting signal score
- 9.91488
- Event
- extremity necrosis
- Reports
- 8
- Reporting signal score
- 32.8348
- Event
- gangrene
- Reports
- 7
- Reporting signal score
- 22.6253
And 56 more, listed on the interactive page.
- NCT00269685
- NCT00481572
- NCT01718613
- NCT00358579
- NCT00628550
- NCT00729794
- NCT05139849
- NCT05738148
- NCT00411879
- NCT03640949
- NCT00420407
- NCT01505231
- NCT01611935
- NCT03483753
- NCT00624650
- NCT01370096
- NCT01606384
- NCT01861015
- NCT01962870
- NCT02975999
- NCT03088345
- NCT03204786
- NCT03446456
- NCT03636451
- NCT03736681
And 4 more, listed on the interactive page.
- Dose
- 0.01-0.1 units/minute
- Route
- Intravenous
- How often
- Every 10 to 15 minutes until target; then taper
- Discard unused solution after 18 hours at room temperature or 24 hours refrigerated
- Titrate to lowest effective dose
- Calculated partition coefficient (XLogP)
- -4.8
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Heavy atoms
- 75
- Molecular formula
- C46H65N15O12S2
- Monoisotopic mass
- 1083.43785492
- Natural product
- No
- 0338-9640
- 0338-9647
- 0517-1020
- 0517-1030
- 0548-9701
- 25021-474
- 55150-370
- 63323-930
- 65219-039
- 68083-520
- 68083-663
- 72572-860
- 84549-370
- 51662-1682
- 51662-1688
- 70121-1642
- 71872-7306
- 81298-8552
- 81298-8554
- Recorded assays
- 471
- Active assays
- 118
- Confirmatory
- Other
- Hemostatics
- Vasoconstrictor Agents
- Antidiuretic Agents
Related records
Trials (90)
- Angiotensin II vs. Vasopressin in Septic Shock
- Argipressin's Influence on Blood Loss During Hepatic Resection
- Arterial Pressure and Stress-Dose Steroids in Cardiac Arrest.
- AVERT Shock: Arginine Vasopressin During the Early Resuscitation of Traumatic Shock
- Brain Imaging Study of Adults With Autism Spectrum Disorders
- CAlcium and VAsopressin Following Injury Early Resuscitation (CAVALIER) Trial
- Cardiac Output Response to Vasopressin Infusion In Abdominal Surgery Patients Under Mechanical Ventilation
- Combined Vasopressin, Methylprednisolone, and Epinephrine for Inhospital Cardiac Arrest
- Comparing Vasopressin and Adrenaline in Patients With Cardiac Arrest
- Comparison of Concentration of Vasopressin During Robot-assisted Laparoscopic Myomectomy
- Comparison of the Effects of Cervical Vasopressin Versus no Premedication on Blood Loss During Vaginal Hysterectomy: A Randomized, Placebo Controlled Trial
- Comparison of Vasopressin and Other Pressors in Septic Shock
- Continuous Infusion of Terlipressin in Septic Shock
- Decision Support for Intraoperative Low Blood Pressure
- Differential Effects of Vasopressin and Oxytocin on Attention Control
- Discontinuation Order of Vasopressors in Septic Shock
- Early Use of Vasopressin in Post-Fontan Management
- Early Versus Late Adjunctive Vasopressin in Septic Shock
- Effect of Vasopressin Versus Norepinephrine on Post-operative Mean Pulmonary Arterial Pressure Following Pulmonary Endarterectomy Surgery,
- Effect of Vasopressin vs Norepinephrine on Pulmonary Oxygenation and Lung Mechanics in Patients With Hypertension Therapy During One-lung Ventilation : Preliminary Study
Approved for (1)
In development for (14)
- Acute lung injury Phase 2
- Autism Phase 2
- Autism spectrum disorder Phase 2
- Benign muscle neoplasm Phase 3
- Cardiac arrest Phase 3
- Congenital heart disease Phase 2
- Heart disorder Phase 3
- Hypotensive disorder Early phase 1
- Leiomyoma Phase 2
- Major depressive disorder Phase 2
- Pulmonary hypertension Phase 2
- Sudden cardiac arrest Phase 2
- Syndromic disease Phase 3
- Toxic shock syndrome Phase 3
Other linked conditions (3)
- Enuresis
- Schizophrenia
- Uterine corpus leiomyoma